A Guide to Oral Obesity Medications

Staff
By Staff
4 Min Read

Oral Semaglutide (Wegovy)

Oral semaglutide (Wegovy) was approved by the U.S. Food and Drug Administration (FDA) in December 2025 as a treatment for weight loss in people with obesity and at least one related health condition. In clinical trials, oral semaglutide helped participants lose an average of 13.6 percent of their total body weight over about 15 months. For someone with a starting weight of 235 lbs, that translates to about 33 lbs of weight loss.
Oral semaglutide is a prescription medication that’s intended to be used in conjunction with a reduced calorie diet and regular physical activity to help adults with obesity and related health problems lose weight. It’s also used to help lower the risk of major cardiovascular events like heart attack and stroke in adults who are overweight or have obesity and also have heart disease. Wegovy is the first oral glucagon-like peptide-1 (GLP-1) agonist approved for these purposes.

Read the full article here

Share This Article
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *